Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 328
Filtrar
1.
Virulence ; 15(1): 2350904, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38725098

RESUMEN

Fusobacterium nucleatum (F. nucleatum) is closely correlated with tumorigenesis in colorectal cancer (CRC). We aimed to investigate the effects of host norepinephrine on the carcinogenicity of F. nucleatum in CRC and reveal the underlying mechanism. The results revealed that both norepinephrine and bacterial quorum sensing (QS) molecule auto-inducer-2 (AI-2) were positively associated with the progression of F. nucleatum related CRC (p < 0.01). In vitro studies, norepinephrine induced upregulation of QS-associated genes and promoted the virulence and proliferation of F. nucleatum. Moreover, chronic stress significantly increased the colon tumour burden of ApcMin/+ mice infected with F. nucleatum (p < 0.01), which was decreased by a catecholamine inhibitor (p < 0.001). Our findings suggest that stress-induced norepinephrine may promote the progression of F. nucleatum related CRC via bacterial QS signalling. These preliminary data provide a novel strategy for the management of pathogenic bacteria by targeting host hormones-bacterial QS inter-kingdom signalling.


Asunto(s)
Neoplasias Colorrectales , Fusobacterium nucleatum , Norepinefrina , Percepción de Quorum , Transducción de Señal , Percepción de Quorum/efectos de los fármacos , Fusobacterium nucleatum/patogenicidad , Fusobacterium nucleatum/efectos de los fármacos , Fusobacterium nucleatum/fisiología , Animales , Neoplasias Colorrectales/microbiología , Norepinefrina/farmacología , Ratones , Humanos , Progresión de la Enfermedad , Infecciones por Fusobacterium/microbiología , Virulencia , Homoserina/análogos & derivados , Homoserina/metabolismo , Ratones Endogámicos C57BL , Masculino , Lactonas
2.
BMC Oral Health ; 24(1): 525, 2024 May 03.
Artículo en Inglés | MEDLINE | ID: mdl-38702623

RESUMEN

OBJECTIVE: To evaluate the antibacterial effectiveness of a combination of ε-poly-L-lysine (ε-PL), funme peptide (FP) as well as domiphen against oral pathogens, and assess the efficacy of a BOP® mouthwash supplemented with this combination in reducing halitosis and supragingival plaque in a clinical trial. MATERIALS AND METHODS: The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the compound against Fusobacterium nucleatum, Porphyromonas gingivalis, Streptococcus mutans, and Aggregatibacter actinomycetemcomitans were determined by the gradient dilution method. Subsequently, the CCK-8 assay was used to detect the toxicity of mouthwash on human gingival fibroblastst, and the effectiveness in reducing halitosis and supragingival plaque of the mouthwash supplemented with the combination was analyzed by a randomized, double-blind, parallel-controlled clinical trial. RESULTS: The combination exhibited significant inhibitory effects on tested oral pathogens with the MIC < 1.56% (v/v) and the MBC < 3.13% (v/v), and the mouthwash containing this combination did not inhibit the viability of human gingival fibroblasts at the test concentrations. The clinical trial showed that the test group displayed notably lower volatile sulfur compounds (VSCs) at 0, 10, 24 h, and 7 d post-mouthwash (P < 0.05), compared with the baseline. After 7 days, the VSC levels of the and control groups were reduced by 50.27% and 32.12%, respectively, and notably cutting severe halitosis by 57.03% in the test group. Additionally, the Plaque Index (PLI) of the test and control group decreased by 54.55% and 8.38%, respectively, and there was a significant difference in PLI between the two groups after 7 days (P < 0.01). CONCLUSIONS: The combination of ε-PL, FP and domiphen demonstrated potent inhibitory and bactericidal effects against the tested oral pathogens, and the newly formulated mouthwash added with the combination exhibited anti-dental plaque and anti-halitosis properties in a clinical trial and was safe. TRIAL REGISTRATION: The randomized controlled clinical trial was registered on Chinese Clinical Trial Registry (No. ChiCTR2300073816, Date: 21/07/2023).


Asunto(s)
Placa Dental , Halitosis , Antisépticos Bucales , Polilisina , Humanos , Halitosis/prevención & control , Halitosis/tratamiento farmacológico , Halitosis/microbiología , Antisépticos Bucales/uso terapéutico , Placa Dental/microbiología , Placa Dental/prevención & control , Método Doble Ciego , Masculino , Femenino , Polilisina/uso terapéutico , Adulto , Pruebas de Sensibilidad Microbiana , Adulto Joven , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Porphyromonas gingivalis/efectos de los fármacos , Fusobacterium nucleatum/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Péptidos/uso terapéutico , Péptidos/farmacología , Aggregatibacter actinomycetemcomitans/efectos de los fármacos , Streptococcus mutans/efectos de los fármacos
3.
ACS Infect Dis ; 10(5): 1612-1623, 2024 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-38597503

RESUMEN

Fusobacterium nucleatum, a pathobiont inhabiting the oral cavity, contributes to opportunistic diseases, such as periodontal diseases and gastrointestinal cancers, which involve microbiota imbalance. Broad-spectrum antimicrobial agents, while effective against F. nucleatum infections, can exacerbate dysbiosis. This necessitates the discovery of more targeted narrow-spectrum antimicrobial agents. We therefore investigated the potential for the fusobacterial enoyl-ACP reductase II (ENR II) isoenzyme FnFabK (C4N14_ 04250) as a narrow-spectrum drug target. ENRs catalyze the rate-limiting step in the bacterial fatty acid synthesis pathway. Bioinformatics revealed that of the four distinct bacterial ENR isoforms, F. nucleatum specifically encodes FnFabK. Genetic studies revealed that fabK was indispensable for F. nucleatum growth, as the gene could not be deleted, and silencing of its mRNA inhibited growth under the test conditions. Remarkably, exogenous fatty acids failed to rescue growth inhibition caused by the silencing of fabK. Screening of synthetic phenylimidazole analogues of a known FabK inhibitor identified an inhibitor (i.e., 681) of FnFabK enzymatic activity and F. nucleatum growth, with an IC50 of 2.1 µM (1.0 µg/mL) and a MIC of 0.4 µg/mL, respectively. Exogenous fatty acids did not attenuate the activity of 681 against F. nucleatum. Furthermore, FnFabK was confirmed as the intracellular target of 681 based on the overexpression of FnFabK shifting MICs and 681-resistant mutants having amino acid substitutions in FnFabK or mutations in other genetic loci affecting fatty acid biosynthesis. 681 had minimal activity against a range of commensal flora, and it was less active against streptococci in physiologic fatty acids. Taken together, FnFabK is an essential enzyme that is amenable to drug targeting for the discovery and development of narrow-spectrum antimicrobial agents.


Asunto(s)
Antibacterianos , Fusobacterium nucleatum , Fusobacterium nucleatum/enzimología , Fusobacterium nucleatum/efectos de los fármacos , Fusobacterium nucleatum/genética , Antibacterianos/farmacología , Antibacterianos/química , Humanos , Enoil-ACP Reductasa (NADH)/genética , Enoil-ACP Reductasa (NADH)/antagonistas & inhibidores , Enoil-ACP Reductasa (NADH)/metabolismo , Pruebas de Sensibilidad Microbiana , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Proteínas Bacterianas/antagonistas & inhibidores , Ácidos Grasos/química , Infecciones por Fusobacterium/microbiología , Infecciones por Fusobacterium/tratamiento farmacológico , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/química
4.
Int J Mol Sci ; 25(8)2024 Apr 11.
Artículo en Inglés | MEDLINE | ID: mdl-38673822

RESUMEN

Complex microbial communities have been reported to be involved in endodontic infections. The microorganisms invade the dental pulp leading to pulpitis and initiating pulp inflammation. Fusobacterium nucleatum is a dominant bacterium implicated in both primary and secondary endodontic infections. Drugs targeting the molecular machinery of F. nucleatum will minimize pulp infection. LpxA and LpxD are early acyltransferases involved in the formation of lipid A, a major component of bacterial membranes. The identification of leads which exhibit preference towards successive enzymes in a single pathway can also prevent the development of bacterial resistance. A stringent screening strategy utilizing physicochemical and pharmacokinetic parameters along with a virtual screening approach identified two compounds, Lomefloxacin and Enoxacin, with good binding affinity towards the early acyltransferases LpxA and LpxD. Lomefloxacin and Enoxacin, members of the fluoroquinolone antibiotic class, exhibit wide-ranging activity against diverse bacterial strains. Nevertheless, their effectiveness in the context of endodontic treatment requires further investigation. This study explored the potential of Lomefloxacin and Enoxacin to manage endodontic infections via computational analysis. Moreover, the compounds identified herein serve as a foundation for devising novel combinatorial libraries with enhanced efficacy for endodontic therapeutic strategies.


Asunto(s)
Antibacterianos , Fusobacterium nucleatum , Lipopolisacáridos , Fusobacterium nucleatum/efectos de los fármacos , Fusobacterium nucleatum/metabolismo , Humanos , Antibacterianos/farmacología , Antibacterianos/química , Lipopolisacáridos/metabolismo , Simulación del Acoplamiento Molecular , Simulación por Computador , Infecciones por Fusobacterium/tratamiento farmacológico , Infecciones por Fusobacterium/microbiología , Enoxacino/farmacología , Proteínas Bacterianas/metabolismo , Pulpitis/tratamiento farmacológico , Pulpitis/metabolismo , Pulpitis/microbiología
5.
J Mater Chem B ; 12(16): 3947-3958, 2024 Apr 24.
Artículo en Inglés | MEDLINE | ID: mdl-38586917

RESUMEN

Colorectal cancer (CRC) occurs in the colorectum and ranks second in the global incidence of all cancers, accounting for one of the highest mortalities. Although the combination chemotherapy regimen of 5-fluorouracil (5-FU) and platinum(IV) oxaliplatin prodrug (OxPt) is an effective strategy for CRC treatment in clinical practice, chemotherapy resistance caused by tumor-resided Fusobacterium nucleatum (Fn) could result in treatment failure. To enhance the efficacy and improve the biocompatibility of combination chemotherapy, we developed an antibacterial-based nanodrug delivery system for Fn-associated CRC treatment. A tumor microenvironment-activated nanomedicine 5-FU-LA@PPL was constructed by the self-assembly of chemotherapeutic drug derivatives 5-FU-LA and polymeric drug carrier PPL. PPL is prepared by conjugating lauric acid (LA) and OxPt to hyperbranched polyglycidyl ether. In principle, LA is used to selectively combat Fn, inhibit autophagy in CRC cells, restore chemosensitivity of 5-FU as well as OxPt, and consequently enhance the combination chemotherapy effects for Fn-associated drug-resistant colorectal tumor. Both in vitro and in vivo studies exhibited that the tailored nanomedicine possessed efficient antibacterial and anti-tumor activities with improved biocompatibility and reduced non-specific toxicity. Hence, this novel anti-tumor strategy has great potential in the combination chemotherapy of CRC, which suggests a clinically relevant valuable option for bacteria-associated drug-resistant cancers.


Asunto(s)
Antineoplásicos , Neoplasias Colorrectales , Fluorouracilo , Ácidos Láuricos , Fluorouracilo/farmacología , Fluorouracilo/química , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/patología , Humanos , Ácidos Láuricos/química , Ácidos Láuricos/farmacología , Animales , Ratones , Antineoplásicos/química , Antineoplásicos/farmacología , Fusobacterium nucleatum/efectos de los fármacos , Oxaliplatino/farmacología , Oxaliplatino/química , Sistemas de Liberación de Medicamentos , Proliferación Celular/efectos de los fármacos , Ensayos de Selección de Medicamentos Antitumorales , Profármacos/química , Profármacos/farmacología , Materiales Biocompatibles/química , Materiales Biocompatibles/farmacología , Antibacterianos/química , Antibacterianos/farmacología , Ratones Endogámicos BALB C , Tamaño de la Partícula , Portadores de Fármacos/química
6.
ACS Appl Mater Interfaces ; 14(1): 390-403, 2022 Jan 12.
Artículo en Inglés | MEDLINE | ID: mdl-34935355

RESUMEN

Silver-based nano-antibiotics are rapidly developing as promising alternatives to conventional antibiotics. Ideally, to remain potent against a wide range of drug-resistant and anaerobic bacteria, silver-based nano-antibiotics should easily penetrate through the bacterial cell walls and actively release silver ions. In this study, highly monodispersed, ultrasmall (<3 nm), polycationic silver nanoclusters (pAgNCs) are designed and synthesized for the elimination of a range of common Gram-negative and Gram-positive pathogens and their corresponding established and matured biofilms, including those composed of multiple species. The pAgNCs also show greatly enhanced antibacterial efficacy against anaerobic bacteria such as Fusobacterium nucleatum and Streptococcus sanguinis. These results demonstrate that the cationic nature facilitates better penetration to the bacterial cell membrane while the presence of a high percentage (>50%) of silver ions (i.e., Ag+ nanoreservoirs) on the cluster surface maintains their efficiency in both aerobic and anaerobic conditions. Significantly, the pAgNCs showed a strong capacity to significantly delay the development of bacterial resistance when compared to similar-sized negatively charged silver nanoparticles or conventional antibiotics. This study demonstrates a novel design strategy that can lay the foundation for the development of future highly potent nano-antibiotics effective against a broad spectrum of pathogens and biofilms needed in many everyday life applications and industries.


Asunto(s)
Antibacterianos/farmacología , Materiales Biocompatibles/farmacología , Nanopartículas/química , Polielectrolitos/farmacología , Plata/farmacología , Antibacterianos/síntesis química , Antibacterianos/química , Materiales Biocompatibles/síntesis química , Materiales Biocompatibles/química , Biopelículas/efectos de los fármacos , Fusobacterium nucleatum/efectos de los fármacos , Iones/química , Iones/farmacología , Ensayo de Materiales , Pruebas de Sensibilidad Microbiana , Tamaño de la Partícula , Polielectrolitos/química , Plata/química , Streptococcus sanguis/efectos de los fármacos
7.
J Mater Chem B ; 9(46): 9594-9605, 2021 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-34783814

RESUMEN

Fusobacterium nucleatum caused drug-resistant around tumor sites often leads to the failure of chemotherapy during colorectal cancer (CRC) treatment. Multifunctional cationic quaternary ammonium materials have been widely used as broad-spectrum antibacterial agents in antibacterial and anticancer fields. Herein, we design a smart supramolecular quaternary ammonium nanoparticle, namely quaternary ammonium PAMAM-AZO@CP[5]A (Q-P-A@CP[5]A), consisting of azobenzene (AZO)-conjugated dendritic cationic quaternary ammonium polyamidoamine (PAMAM) as the core and carboxylatopillar[5]arene (CP[5]A)-based switch, for antibacterial and anti-CRC therapies. The quaternary ammonium-PAMAM-AZO (Q-P-A) core endows the supramolecular system with enhanced antibacterial and anticancer properties. -N+CH3 groups on the surface of Q-P-A are accommodated in the CP[5]A cavity under normal conditions, which significantly improves the biocompatibility of Q-P-A@CP[5]A. Meanwhile, the CP[5]A host can be detached from -N+CH3 groups under pathological conditions, achieving efficient antibacterial and antitumor therapies. Furthermore, azoreductase in the tumor site can break the -NN- bonds of AZO in Q-P-A@CP[5]A, leading to the morphology recovery of supramolecular nanoparticles and CRC therapy through inducing cell membrane rupture. Both in vitro and in vivo experiments demonstrate that Q-P-A@CP[5]A possesses good biocompatibility, excellent antibacterial effect, and CRC treatment capability with negligible side effects. This supramolecular quaternary ammonium system provides an effective treatment method to overcome chemotherapy-resistant cancer caused by bacteria.


Asunto(s)
Fusobacterium nucleatum/efectos de los fármacos , Nanopartículas/química , Poliaminas/química , Compuestos de Amonio Cuaternario/química , Animales , Antibacterianos , Antifúngicos , Antineoplásicos/química , Antineoplásicos/farmacología , Apoptosis , Compuestos Azo/química , Supervivencia Celular , Diseño de Fármacos , Farmacorresistencia Fúngica , Resistencia a Antineoplásicos , Células HT29 , Humanos , Masculino , Ratones , Ratones Desnudos , Modelos Moleculares , Estructura Molecular , Neoplasias Experimentales , Ensayos Antitumor por Modelo de Xenoinjerto
8.
ACS Appl Mater Interfaces ; 13(42): 49642-49657, 2021 Oct 27.
Artículo en Inglés | MEDLINE | ID: mdl-34637255

RESUMEN

Periodontitis compromises the integrity and function of tooth-supporting structures. Although therapeutic approaches have been offered, predictable regeneration of periodontal tissues remains intangible, particularly in anatomically complex defects. In this work, personalized and defect-specific antibiotic-laden polymeric scaffolds containing metronidazole (MET), tetracycline (TCH), or their combination (MET/TCH) were created via electrospinning. An initial screening of the synthesized fibers comprising chemo-morphological analyses, cytocompatibility assessment, and antimicrobial validation against periodontopathogens was accomplished to determine the cell-friendly and anti-infective nature of the scaffolds. According to the cytocompatibility and antimicrobial data, the 1:3 MET/TCH formulation was used to obtain three-dimensional defect-specific scaffolds to treat periodontally compromised three-wall osseous defects in rats. Inflammatory cell response and new bone formation were assessed by histology. Micro-computerized tomography was performed to assess bone loss in the furcation area at 2 and 6 weeks post implantation. Chemo-morphological and cell compatibility analyses confirmed the synthesis of cytocompatible antibiotic-laden fibers with antimicrobial action. Importantly, the 1:3 MET/TCH defect-specific scaffolds led to increased new bone formation, lower bone loss, and reduced inflammatory response when compared to antibiotic-free scaffolds. Altogether, our results suggest that the fabrication of defect-specific antibiotic-laden scaffolds holds great potential toward the development of personalized (i.e., patient-specific medication) scaffolds to ablate infection while affording regenerative properties.


Asunto(s)
Antibacterianos/farmacología , Metronidazol/farmacología , Periodontitis/tratamiento farmacológico , Tetraciclina/farmacología , Andamios del Tejido/química , Antibacterianos/química , Regeneración Ósea/efectos de los fármacos , Fusobacterium nucleatum/efectos de los fármacos , Ensayo de Materiales , Metronidazol/química , Pruebas de Sensibilidad Microbiana , Tamaño de la Partícula , Periodontitis/microbiología , Periodontitis/patología , Porphyromonas gingivalis/efectos de los fármacos , Prevotella intermedia/efectos de los fármacos , Tetraciclina/química
9.
Food Funct ; 12(21): 10470-10483, 2021 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-34554173

RESUMEN

Cranberries are widely recognized as a functional food that can promote oral health. However, the high concentration of organic acids in cranberry juice can cause tooth enamel erosion. Electrodialysis with bipolar membrane (EDBM) is a process used for the deacidification of cranberry juice. The present study investigated whether the removal of organic acids (0%, 19%, 42%, 60%, and 79%) from cranberry juice by EDBM affects its antibacterial activity against major periodontopathogens as well as its anti-inflammatory properties in an oral epithelial cell model. A deacidification rate ≥60% attenuated the bactericidal effect against planktonic and biofilm-embedded Aggregatibacter actinomycetemcomitans but had no impact on Porphyromonas gingivalis and Fusobacterium nucleatum. Cranberry juice increased the adherence of A. actinomycetemcomitans and P. gingivalis to oral epithelial cells, but reduced the adherence of F. nucleatum by half regardless of the deacidification rate. F. nucleatum produced more hydrogen sulfide when it was exposed to deacidified cranberry juice with a deacidification rate ≥42% compared to the raw beverage. Interestingly, the removal of organic acids from cranberry juice lowered the cytotoxicity of the beverage for oral epithelial cells. Deacidification attenuated the anti-inflammatory effect of cranberry juice in an in vitro oral epithelial cell model. The secretion of IL-6 by lipopolysaccharide (LPS)-stimulated oral epithelial cells exposed to cranberry juice increased proportionally with the deacidification rate. No such effect was observed with respect to the production of IL-8. This study provided evidence that organic acids, just like phenolic compounds, might contribute to the health benefits of cranberry juice against periodontitis.


Asunto(s)
Aggregatibacter actinomycetemcomitans/efectos de los fármacos , Antibacterianos/farmacología , Antiinflamatorios/farmacología , Fusobacterium nucleatum/efectos de los fármacos , Extractos Vegetales/farmacología , Porphyromonas gingivalis/efectos de los fármacos , Vaccinium macrocarpon/química , Ácidos/química , Antibacterianos/química , Antiinflamatorios/química , Biopelículas , Células Cultivadas , Técnicas Electroquímicas/métodos , Células Epiteliales/efectos de los fármacos , Jugos de Frutas y Vegetales , Extractos Vegetales/química
10.
J Infect Dev Ctries ; 15(7): 1027-1031, 2021 07 31.
Artículo en Inglés | MEDLINE | ID: mdl-34343129

RESUMEN

INTRODUCTION: Propolis is a natural composite balsam. In the past decade, propolis has been extensively investigated as an adjuvant for the treatment of periodontitis. This study aimed to investigate antimicrobial activities of propolis solutions and plant essential oils against some oral cariogenic (Streptococcus mutans, Streptococcus mitis, Streptococcus sanguis, Lactobacillus acidophilus) and periodontopathic bacteria (Actinomyces odontolyticus, Eikenella corrodens, Fusobacterium nucleatum). METHODOLOGY: Determination of the minimum inhibitory concentration (MIC): The antimicrobial activity of propolis and essential oils was investigated by the agar dilution method. Serial dilutions of essential oils were prepared in plates, and the assay plates were estimated to contain 100, 50, 25 and 12.5 µg/mL of active essential oils. Dilutions for propolis were 50, 25, 12.5 and 6.3 µg/mL of active propolis solutions. RESULTS: Propolis solutions dissolved in benzene, diethyl ether and methyl chloride, demonstrated equal effectiveness against all investigated oral bacteria (MIC=12.5 µg/mL). Propolis solution dissolved in acetone displayed MIC of 6.3 µg/mL only for Lactobacillus acidophilus. At the MIC of 12.5 µg/mL, essential oils of Salvia officinalis and Satureja kitaibelii were effective against Streptococcus mutans and Porphyromonas gingivalis, respectively. For the latter, the MIC value of Salvia officinalis was twice higher. CONCLUSIONS: The results indicate that propolis and plant essential oils appear to be a promising source of antimicrobial agents that may prevent dental caries and other oral infectious diseases.


Asunto(s)
Antiinfecciosos/farmacología , Lactobacillus acidophilus/efectos de los fármacos , Aceites Volátiles/farmacología , Porphyromonas gingivalis/efectos de los fármacos , Própolis/farmacología , Streptococcus mutans/efectos de los fármacos , Actinomyces/efectos de los fármacos , Eikenella corrodens/efectos de los fármacos , Fusobacterium nucleatum/efectos de los fármacos , Humanos , Pruebas de Sensibilidad Microbiana , Boca/microbiología , Estudios Prospectivos , Salvia officinalis/química , Satureja/química , Streptococcus mitis/efectos de los fármacos , Streptococcus sanguis/efectos de los fármacos
11.
Molecules ; 26(16)2021 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-34443332

RESUMEN

Peptoids (oligo N-substituted glycines) are peptide analogues, which can be designed to mimic host antimicrobial peptides, with the advantage that they are resistant to proteolytic degradation. Few studies on the antimicrobial efficacy of peptoids have focused on Gram negative anaerobic microbes associated with clinical infections, which are commonly recalcitrant to antibiotic treatment. We therefore studied the cytotoxicity and antibiofilm activity of a family of peptoids against the Gram negative obligate anaerobe Fusobacterium nucleatum, which is associated with infections in the oral cavity. Two peptoids, peptoid 4 (NaeNpheNphe)4 and peptoid 9 (NahNspeNspe)3 were shown to be efficacious against F. nucleatum biofilms at a concentration of 1 µM. At this concentration, peptoids 4 and 9 were not cytotoxic to human erythrocytes or primary human gingival fibroblast cells. Peptoids 4 and 9 therefore have merit as future therapeutics for the treatment of oral infections.


Asunto(s)
Biopelículas/efectos de los fármacos , Fusobacterium nucleatum/efectos de los fármacos , Fusobacterium nucleatum/fisiología , Peptoides/farmacología , Biopelículas/crecimiento & desarrollo , Farmacorresistencia Bacteriana/efectos de los fármacos
12.
Probiotics Antimicrob Proteins ; 13(6): 1808-1819, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34402021

RESUMEN

This study evaluated the cytocompatibility and antimicrobial/antibiofilm effects of epigallocatechin-3-gallate (EGCG) associated with peptide LL-37 and its analogue KR-12-a5 against oral pathogens. The effect of the compounds on metabolism of fibroblasts was evaluated by methyltetrazolium assays. Antimicrobial activity of the compounds was evaluated on Streptococcus mutans, Enterococcus faecalis, Actinomyces israelii, and Fusobacterium nucleatum under planktonic conditions, on single- and dual-species biofilms and E. faecalis biofilms in dentinal tubules and analyzed by bacterial counts and confocal microscopy. Data were statistically analyzed considering p < 0.05. EGCG and peptide combinations were not toxic to fibroblasts. KR-12-a5 showed synergistic or addictive effects with EGCG and LL-37 against all bacteria tested. However, EGCG associated with KR-12-a5 demonstrated the highest bactericidal activity on all bacteria tested, at lower concentrations. In single-species biofilms, EGCG + KR-12-a5 eliminated S. mutans and A. israelii and reduced E. faecalis and F. nucleatum counts around 5 log CFU/mL. EGCG + KR-12-a5 reduced E. faecalis (-3.93 log CFU/mL) and eliminated S. mutans in dual-species biofilms. No growth of E. faecalis and significant reduction in A. israelii (-6.24 log CFU/mL) and F. nucleatum (-4.62 log CFU/mL) counts were detected in dual-species biofilms. The combination of EGCG and KR-12-a5 led to 88% of E. faecalis dead cells inside dentin tubules. The association of EGCG and KR-12-a5 was cytocompatible and promoted synergistic effect against biofilms of bacteria associated with endodontic infections.


Asunto(s)
Antiinfecciosos , Biopelículas/efectos de los fármacos , Catequina/análogos & derivados , Péptidos/farmacología , Actinomyces/efectos de los fármacos , Antiinfecciosos/farmacología , Catequina/farmacología , Enterococcus faecalis/efectos de los fármacos , Fusobacterium nucleatum/efectos de los fármacos , Streptococcus mutans/efectos de los fármacos
13.
APMIS ; 129(11): 626-630, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34418158

RESUMEN

Species (spp.) belonging to the genus Fusobacterium are anaerobic commensals colonizing the upper respiratory tract, the gastrointestinal tract, and the genitals. Infections with Fusobacterium spp. have been reported at many anatomical sites, including pneumonias and pleural empyemas; however, there are very few published cases of Fusobacterium spp. causing spondylodiscitis or fistulas. Bone infections with Fusobacterium can spread directly to surrounding muscular tissue or by hematogenous transmission to any other tissue including pleurae and lungs. Similarly, pleural infections can spread Fusobacterium spp. to any other tissue including fistulas and bone. Concomitant pleural empyema and spondylodiscitis are rare; however, there are a few published cases with concomitant disease, although none caused by Fusobacterium spp. A 77-year-old female patient was assessed using computed tomography (CT) scanning of the thorax and abdomen, as well as analyses of fluid drained from the region affected by the pleural empyema. A diagnosis of Fusobacterium empyema, fistula, bacteremia, and spondylodiscitis was made, and the patient's condition improved significantly after drainage of the pleural empyema and relevant long-term antibiotic treatment. We describe the first confirmed case with concomitant infection with Fusobacterium nucleatum as spondylodiscitis and pleural empyema connected by a fistula.


Asunto(s)
Discitis/etiología , Empiema Pleural/etiología , Fístula/etiología , Infecciones por Fusobacterium/complicaciones , Fusobacterium nucleatum/patogenicidad , Anciano , Antibacterianos/uso terapéutico , Bacteriemia/diagnóstico , Bacteriemia/tratamiento farmacológico , Bacteriemia/etiología , Discitis/diagnóstico , Discitis/tratamiento farmacológico , Empiema Pleural/diagnóstico , Empiema Pleural/tratamiento farmacológico , Femenino , Fístula/diagnóstico , Fístula/tratamiento farmacológico , Infecciones por Fusobacterium/diagnóstico , Infecciones por Fusobacterium/tratamiento farmacológico , Fusobacterium nucleatum/efectos de los fármacos , Humanos , Pleura/diagnóstico por imagen , Pleura/microbiología , Resultado del Tratamiento
14.
Anaerobe ; 71: 102420, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34314865

RESUMEN

A 42-year-old man was referred to the Department of Orthopedic Surgery with pain over his right greater trochanter and signs of systemic infection. CT showed an enhanced mass in his gluteus maximus as well as gas in the biceps femoris over the underlying hip joint. Tissue biopsy yielded Fusobacterium nucleatum and Actinomyces turicensis. The patient was successfully treated for 6 weeks with amoxicillin/clavulanic acid 875mg/125mg and metronidazole 500mg.


Asunto(s)
Actinomycetaceae/aislamiento & purificación , Infecciones por Actinomycetales/microbiología , Bacteriemia/microbiología , COVID-19/inmunología , Infecciones por Fusobacterium/microbiología , Fusobacterium nucleatum/aislamiento & purificación , Cadera/microbiología , Absceso/tratamiento farmacológico , Absceso/microbiología , Actinomycetaceae/efectos de los fármacos , Actinomycetaceae/genética , Infecciones por Actinomycetales/tratamiento farmacológico , Adulto , Antibacterianos/uso terapéutico , COVID-19/virología , Infecciones por Fusobacterium/tratamiento farmacológico , Fusobacterium nucleatum/efectos de los fármacos , Fusobacterium nucleatum/genética , Humanos , Huésped Inmunocomprometido , Masculino , SARS-CoV-2/genética , SARS-CoV-2/aislamiento & purificación
15.
PLoS One ; 16(5): e0252029, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34029354

RESUMEN

Fusobacterium nucleatum is associated with many conditions and diseases, including periodontal diseases that affect tooth-supporting tissues. The aim of the present study was to investigate the effects of a cocoa extract (Theobroma cacao L.) on F. nucleatum with respect to growth, biofilm formation, adherence, and hydrogen sulfide (H2S) production. The anti-inflammatory properties and the effect on epithelial barrier function of the cocoa extract were also assessed. The cocoa extract, whose major phenolic compound is epicatechin, dose-dependently inhibited the growth, biofilm formation, adherence properties (basement membrane matrix, oral epithelial cells), and H2S production of F. nucleatum. It also decreased IL-6 and IL-8 production by F. nucleatum-stimulated oral epithelial cells and inhibited F. nucleatum-induced NF-κB activation in monocytes. Lastly, the cocoa extract enhanced the barrier function of an oral epithelial model by increasing the transepithelial electrical resistance. We provide evidence that the beneficial properties of an epicatechin-rich cocoa extract may be useful for preventing and/or treating periodontal diseases.


Asunto(s)
Cacao/química , Fusobacterium nucleatum/efectos de los fármacos , Enfermedades Periodontales/tratamiento farmacológico , Fenoles/farmacología , Biopelículas/efectos de los fármacos , Catequina/química , Catequina/farmacología , Adhesión Celular/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Fusobacterium nucleatum/patogenicidad , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Sulfuro de Hidrógeno/metabolismo , Interleucina-6/genética , Interleucina-8/genética , Monocitos/efectos de los fármacos , Enfermedades Periodontales/microbiología , Fenoles/química , Extractos Vegetales/química , Extractos Vegetales/farmacología
16.
Tohoku J Exp Med ; 253(4): 249-259, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33840648

RESUMEN

Bacterial infection contributes to tumor development and malignant progression. Fusobacterium nucleatum (F. nucleatum) is reported to promote oral squamous cell carcinoma. However, molecular bases of F. nucleatum regulating oral cancer cells have not been fully elucidated. We report here that F. nucleatum down-regulates p53 and E-cadherin via the Wnt/NFAT pathway to promote cisplatin-resistance and migration in oral squamous carcinoma cells. We pretreated Cal-27 and HSC-3 cells with F. nucleatum and the survival rates against cysplatin (Cis-diamminedichloroplatinum, CDDP) were significantly higher in treated cells. The expressions of migration and apoptosis-related proteins like E-cadherin and p53 were lower in western blot analysis. We observed that F. nucleatum was an activator of the Wnt/NFAT pathway. The expression levels of the Wnt pathway gene wnt5a and Nuclear factors of activated T cells 3 (NFATc3) were notably higher in treated cells. With the inhibition effect of NFAT-inhibitory peptide VIVIT, the expressions of E-cadherin and p53 in response to F. nucleatum infection were up-regulated reversely. We concluded that F. nucleatum might promote cisplatin-resistance and migration of oral squamous cell carcinoma cells through the Wnt/NFAT pathway.


Asunto(s)
Movimiento Celular , Cisplatino/farmacología , Fusobacterium nucleatum/fisiología , Neoplasias de Cabeza y Cuello/genética , Factores de Transcripción NFATC/genética , Carcinoma de Células Escamosas de Cabeza y Cuello/genética , Regulación hacia Arriba/genética , Proteína Wnt-5a/genética , Apoptosis/efectos de los fármacos , Apoptosis/genética , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Movimiento Celular/genética , Resistencia a Antineoplásicos/efectos de los fármacos , Resistencia a Antineoplásicos/genética , Fusobacterium nucleatum/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Neoplasias de Cabeza y Cuello/microbiología , Neoplasias de Cabeza y Cuello/patología , Humanos , Factores de Transcripción NFATC/metabolismo , Oligopéptidos/farmacología , Carcinoma de Células Escamosas de Cabeza y Cuello/microbiología , Carcinoma de Células Escamosas de Cabeza y Cuello/patología , Proteína Wnt-5a/metabolismo
17.
FEMS Microbiol Lett ; 368(7)2021 05 03.
Artículo en Inglés | MEDLINE | ID: mdl-33885765

RESUMEN

The enzyme L-methionine-γ-lyase is commonly found in a wide range of bacteria and catalyzes the α-elimination and γ-elimination of L-methionine to produce methyl mercaptan, α-ketobutyrate and ammonia. Black cumin seed essential oil (BC oil) reportedly exhibits deodorizing activity against methyl mercaptan. Therefore, we hypothesized that BC oil may also suppress methyl mercaptan production. In this study, we aimed to evaluate the inhibitory effect of BC oil on L-methionine-γ-lyase activity in Fusobacterium nucleatum. Recombinant L-methionine-γ-lyase was incubated under appropriate conditions with BC oil and its constituent thymoquinone. To analyze L-methionine-γ-lyase activity, α-ketobutyric acid and ammonia concentrations were determined. The concentrations of α-ketobutyric acid and ammonia were significantly decreased by 10 µg mL-1 of BC oil (P < 0.01) and 16.4 µg/mL of thymoquinone (P < 0.05). An enzyme kinetic assay showed a mixed inhibition pattern between L-methionine-γ-lyase and thymoquinone. In conclusion, BC oil not only had a deodorizing effect against methyl mercaptan but also an inhibitory effect on methyl mercaptan production through the suppression of L-methionine-γ-lyase activity. Thymoquinone may be mainly responsible for these effects of BC oil. Thus, application of natural BC oil may be adapted not only for medical use but also in other areas of life.


Asunto(s)
Antibacterianos/farmacología , Liasas de Carbono-Azufre/antagonistas & inhibidores , Fusobacterium nucleatum/efectos de los fármacos , Nigella sativa/química , Aceites Volátiles/farmacología , Amoníaco/metabolismo , Benzoquinonas/farmacología , Butiratos/metabolismo , Liasas de Carbono-Azufre/metabolismo , Fusobacterium nucleatum/enzimología , Fusobacterium nucleatum/metabolismo , Metionina/metabolismo , Pruebas de Sensibilidad Microbiana , Proteínas Recombinantes/metabolismo , Semillas/química
18.
mBio ; 12(2)2021 04 06.
Artículo en Inglés | MEDLINE | ID: mdl-33824205

RESUMEN

Aspirin is a chemopreventive agent for colorectal adenoma and cancer (CRC) that, like many drugs inclusive of chemotherapeutics, has been investigated for its effects on bacterial growth and virulence gene expression. Given the evolving recognition of the roles for bacteria in CRC, in this work, we investigate the effects of aspirin with a focus on one oncomicrobe-Fusobacterium nucleatum We show that aspirin and its primary metabolite salicylic acid alter F. nucleatum strain Fn7-1 growth in culture and that aspirin can effectively kill both actively growing and stationary Fn7-1. We also demonstrate that, at levels that do not inhibit growth, aspirin influences Fn7-1 gene expression. To assess whether aspirin modulation of F. nucleatum may be relevant in vivo, we use the ApcMin/+ mouse intestinal tumor model in which Fn7-1 is orally inoculated daily to reveal that aspirin-supplemented chow is sufficient to inhibit F. nucleatum-potentiated colonic tumorigenesis. We expand our characterization of aspirin sensitivity across other F. nucleatum strains, including those isolated from human CRC tissues, as well as other CRC-associated microbes, enterotoxigenic Bacteroides fragilis, and colibactin-producing Escherichia coli Finally, we determine that individuals who use aspirin daily have lower fusobacterial abundance in colon adenoma tissues, as determined by quantitative PCR performed on adenoma DNA. Together, our data support that aspirin has direct antibiotic activity against F. nucleatum strains and suggest that consideration of the potential effects of aspirin on the microbiome holds promise in optimizing risk-benefit assessments for use of aspirin in CRC prevention and management.IMPORTANCE There is an increasing understanding of the clinical correlations and potential mechanistic roles of specific members of the gut and tumoral microbiota in colorectal cancer (CRC) initiation, progression, and survival. However, we have yet to parlay this knowledge into better CRC outcomes through microbially informed diagnostic, preventive, or therapeutic approaches. Here, we demonstrate that aspirin, an established CRC chemopreventive, exhibits specific effects on the CRC-associated Fusobacterium nucleatum in culture, an animal model of intestinal tumorigenesis, and in human colonic adenoma tissues. Our work proposes a potential role for aspirin in influencing CRC-associated bacteria to prevent colorectal adenomas and cancer, beyond aspirin's canonical anti-inflammatory role targeting host tissues. Future research, such as studies investigating the effects of aspirin on fusobacterial load in patients, will help further elucidate the prospect of using aspirin to modulate F. nucleatumin vivo for improving CRC outcomes.


Asunto(s)
Adenoma/microbiología , Aspirina/administración & dosificación , Aspirina/farmacología , Neoplasias Colorrectales/microbiología , Fusobacterium nucleatum/efectos de los fármacos , Animales , Bacterias/efectos de los fármacos , Bacterias/patogenicidad , Carcinogénesis , Transformación Celular Neoplásica , Colon/efectos de los fármacos , Colon/microbiología , Neoplasias Colorrectales/prevención & control , Femenino , Fusobacterium nucleatum/genética , Fusobacterium nucleatum/patogenicidad , Humanos , Masculino , Ratones
19.
FEMS Microbiol Lett ; 368(5)2021 04 08.
Artículo en Inglés | MEDLINE | ID: mdl-33693760

RESUMEN

Probiotics is widespreadly used nowadays. However, the safety issue with the use of live probiotics is still a matter of contention. In recent years, an expanding body of evidence supports the beneficial role of heat-killed probiotics in the maintenance of systemic health, whereas the role of these heat-killed bacteria on periodontal health remains unclear. This study aimed to evaluate the effects of heat-killed probiotics on periodontal pathogen virulence and associated mechanisms. We demonstrated that heat-killed Lactobacillus acidophilus was able to coaggregate with Fusobacterium nucleatum, the bridging bacteria of oral biofilm, and inhibit the adhesion and invasion of F. nucleatum, leading to a subsequent elimination of pro-inflammatory cytokine production in oral epithelial cells. This coaggregation further caused a suppression of the virulence gene fap2 expression in F. nucleatum. Therefore, heat-killed L. acidophilus might downregulate the pro-inflammatory cytokine expression in epithelial cells via coaggregation with F. nucleatum and suppression of F. nucleatum fap2 expression, which was the first demonstration that heat-killed probiotics modulate periodontal disease pathogenesis via coaggregation. Collectively, this finding provides new evidence that heat-killed probiotics might exert beneficial effects to periodontal health by coaggregating with periodontal pathogens and modulating their virulence.


Asunto(s)
Adhesión Bacteriana/efectos de los fármacos , Infecciones por Fusobacterium/terapia , Fusobacterium nucleatum/efectos de los fármacos , Lactobacillus acidophilus/metabolismo , Enfermedades Periodontales/tratamiento farmacológico , Probióticos/farmacología , Biopelículas/crecimiento & desarrollo , Línea Celular Tumoral , Citocinas/biosíntesis , Citocinas/inmunología , Células Epiteliales/inmunología , Células Epiteliales/microbiología , Fusobacterium nucleatum/inmunología , Fusobacterium nucleatum/patogenicidad , Calor , Humanos , Enfermedades Periodontales/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...